Ketamine and transcranial magnetic stimulation treatment for bipolar II disorder: a case report

Journal of Medical Case Reports

Dan G Pavel²  Brian P Griffin³  Steven RD Best¹ 

[1] The Neuroscience Center, 440 Lake Cook Road, Building 2, Deerfield 60015, IL, USA;PathFinder Brain SPECT, 440 Lake Cook Road, Suite 3, Deerfield 60015, IL, USA;Independent Practice, 333 East Ontario Suite 1203B, Chicago, IL, USA

关键词: Bipolar II;    TMS;    Transcranial magnetic stimulation;    Ketamine;   

Others  :  1180770
DOI  :  10.1186/s13256-015-0520-0

 received in 2014-08-16, accepted in 2015-01-08,  发布年份 2015

【 摘 要 】

Introduction

To the best of our knowledge, this is the first case report of successful treatment for bipolar II disorder using a combined ketamine and transcranial magnetic stimulation treatment.

Case presentation

A 43-year-old Caucasian unemployed man presented to us with treatment-resistant bipolar II disorder, currently in a mixed state. A psychometric assessment and brain single-photon emission computer tomography scan were conducted at baseline. His psychometric assessment revealed severe depressive and manic symptoms that were consistent with bipolar II disorder. Findings from a brain single-photon emission computer tomography scan converged with those from his psychometric assessment. The combined ketamine and transcranial magnetic stimulation treatment was administered a total of 24 times over five months, with his ketamine dosage increased from 50mg at the first treatment to 600mg by the last. Starting after the second treatment, he reported substantial improvements in his symptoms. A follow-up psychometric assessment and brain single-photon emission computer tomography scan five months later revealed substantial blood flow increases in the previously deficient areas.

Conclusions

We provide preliminary evidence for a treatment method that magnifies the therapeutic benefits of infused ketamine along with transcranial magnetic stimulation. We postulate that this may be based on an interaction at the level of the relevant cortico-thalamo-cortical circuit(s).

【 授权许可】

   
2015 Best et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ghasemi M, Phillips C, Trillo L, De Miguel Z, Das D, Salehi A. The role of NMDA receptors in the pathophysiology and treatment of mood disorders. Neurosci Biobehav Rev. 2014; 47:336-58.
• [2]Naughton M, Clark G, O’Leary OF, Cryan JF, Dinan TG. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord. 2014; 156:24-35.
• [3]Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A et al.. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012; 71:939-46.
• [4]Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan HR et al.. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2012; 74:250-6.
• [5]Lazzaro VD, Oliviero A, Profice P, Pennisi MA, Pilato F, Zito G et al.. Ketamine increases human motor cortex excitability to transcranial magnetic stimulation. J Physiology. 2003; 547:485-96.
• [6]Llinas RR, Ribary U, Jeanmonod D, Kronberg E, Mitras PP. Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc Natl Acad Sci. 1999; 96:15222-7.
• [7]Thut G, Veniero D, Romei V, Miniussi C, Schyns P, Gross J. Rhythmic TMS causes local entrainment of natural oscillatory signatures. Curr Biol. 2011; 21:1176-85.
• [8]Johnson JS, Hamidi M, Postle BR. Using EEG to explore how rTMS produces its effects on behavior. Brain Topogr. 2010; 22:281-93.
• [9]Catafau AM. Brain SPECT in clinical practice. Part I: perfusion. J Nucl Med. 2001; 42:259-71.
• [10]Holman BL, Devous MD. Functional brain SPECT: the emergence of a powerful clinical method. J Nucl Med. 1992; 33:1888-904.
• [11]Minoshima S, Koepe RA, Frey KA, Kuhl DE. Anatomical standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994; 35:1528-37.
• [12]Juni JE, Waxman AD, Devous MD, Tikofsky RS, Ichise M, Van Heertum RL et al.. Procedure guidelines for brain perfusion SPECT using 99mTc radiopharmaceuticals 3.0. J Nucl Med Technol. 2009; 37:191-5.
• [13]Pliszka SR, Glahn DC, Semrud-Clikeman M, Franklin C, Perez R, Xiong J et al.. Neuroimaging of inhibitory control areas in children with attention deficit hyperactivity disorder who were treatment naïve or in long-term treatment. Am J Psychiatry. 2006; 163:1052-60.
• [14]Sheehan W, Thurber S. Review of two years of experiences with SPECT among psychiatric patients in a rural hospital setting. J Psychiatr Pract. 2008; 14:318-23.
• [15]Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C et al.. Deep brain stimulation for treatment-resistant depression. Neuron. 2005; 45:651-60.
• [16]Best S. Rapid relief of treatment resistant depression by facilitated ketamine infusion: a preliminary report. Activ Nerv Super. 2014; 56:28-36.